home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Arsenal Files 6
/
The Arsenal Files 6 (Arsenal Computer).ISO
/
health
/
med9603.zip
/
M9630122.TXT
< prev
next >
Wrap
Text File
|
1996-02-27
|
3KB
|
45 lines
Document 0122
DOCN M9630122
TI 3D-quantitative structure-activity relationships of human
immunodeficiency virus type-1 proteinase inhibitors: comparative
molecular field analysis of 2-heterosubstituted statine
derivatives-implications for the design of novel inhibitors.
DT 9603
AU Kroemer RT; Ettmayer P; Hecht P; SANDOZ Forschungsinstitut Ges. m.b.H,
Vienna, Austria.
SO J Med Chem. 1995 Dec 8;38(25):4917-28. Unique Identifier : AIDSLINE
MED/96105434
AB A set of 100 novel 2-heterosubstituted statine derivatives inhibiting
human immunodeficiency virus type-1 proteinase has been investigated by
comparative molecular field analysis. In order to combine the structural
information available from X-ray analyses with a predictive quantitative
structure-activity relationship (QSAR) model, docking experiments of a
prototype compound into the receptor were performed, and the 'active
conformation' was determined. The structure of the receptor was taken
from the published X-ray analysis of the proteinase with bound MVT-101,
the latter compound exhibiting high structural similarity with the
inhibitors investigated. The validity of the resulting QSARs was
confirmed in four different ways. (1) The common parameters, namely, the
cross-validated r2 values obtained by the leave-one-out (LOO) method
(r2cv = 0.572-0.593), and (2) the accurate prediction of a test set of
67 compounds (q2 = 0.552-0.569) indicated a high consistency of the
models. (3) Repeated analyses with two randomly selected
cross-validation groups were performed and the cross-validated r2 values
monitored. The resulting average r2 values were of similar magnitudes
compared to those obtained by the LOO method. (4) The coefficient fields
were compared with the steric and electrostatic properties of the
receptor and showed a high level of compatibility. Further analysis of
the results led to the design of a novel class of highly active
compounds containing an additional linkage between P1' and P3'. The
predicted activities of these inhibitors were also in good agreement
with the experimentally determined values.
DE Amino Acids/*CHEMISTRY/PHARMACOLOGY Antiviral
Agents/*CHEMISTRY/PHARMACOLOGY Computer Graphics Crystallography,
X-Ray Drug Design Human Hydrogen Bonding HIV Protease
Inhibitors/*CHEMISTRY/PHARMACOLOGY HIV-1/*METABOLISM Models, Molecular
Structure-Activity Relationship JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).